This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound WATCH-LIST HIGH

Nortadalafil

Extended Research
Extended Research

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

Editor's verdict WATCH-LIST HIGH

Nortadalafil has no upside over the FDA-approved parent (tadalafil) for any user with legitimate access. Tadalafil generic is $0.30-0.80 per 20mg pill via the same Indian pharmacies that sell modafinil — same gray-market sourcing reality, but with 20+ years of safety data, validated PK, and FDA-grade purity. Nortadalafil's only purchase is "research-chem-only sourcing" framing — i.e., scenarios where you genuinely cannot get tadalafil. For a 20yo with telehealth access AND existing Indian-pharmacy supplier relationships, that scenario is hypothetical. Stays on watch-list because the class itself is interesting (the cognitive-flow / vascular hedge is real for tadalafil) and because nortadalafil shows up as an adulterant in counterfeit "natural male enhancement" products — worth knowing how to recognize and avoid. Verdict would change to SKIP-ALWAYS only if FDA escalated to schedule it; would never change to OPTIONAL-ADD because the cleaner alternative dominates.

Research pass: thorough
Decision matrix by user profile Per-archetype
  • 20-30, brain-priority, high cognitive workload (this archetype)
    WATCH-LIST

    Tadalafil dominates on every axis. The only "value" of nortadalafil literacy is recognizing it on FDA recall lists.

  • 30-50, executive maintenance
    WATCH-LIST

    Same reasoning. Tadalafil daily 2.5-5 mg is the actual play here.

  • 50+, mild cognitive decline
    WATCH-LIST

    The dementia-incidence observational signal is for tadalafil/sildenafil, not nortadalafil. Use the validated parent compound.

  • Anxiety-prone
    WATCH-LIST

    Class is neutral on anxiety; no reason to introduce purity uncertainty.

  • High athletic load, tested status
    WATCH-LIST

    PDE5i are not currently WADA-banned, but counterfeit supplements often co-contain banned anabolics — purity uncertainty is the issue.

  • Sleep-disordered
    WATCH-LIST

    Class doesn't affect sleep architecture.

  • Recovery-focused (post-injury, post-illness)
    WATCH-LIST
  • Strength/anabolic-focused
    WATCH-LIST
  • Curious about the cognitive-flow / vascular hedge
    U

    tadalafil daily 2.5 mg, not nortadalafil. The case for the class is the case for tadalafil specifically.

Subjective experience (deep)

(All from gray-market RC-vendor reports — extremely low-confidence, no controlled trial data.)

  • Onset: ~30-60 min oral (faster than tadalafil per gray-market reports — consistent with the more polar / more rapidly absorbed structural argument)
  • Peak: ~1-3 hr
  • Plateau: ~4-6 hr (much shorter than tadalafil's 24-36 hr "weekend pill" plateau)
  • Taper: trails out by ~10-12 hr
  • Characteristic effects (claimed): vasodilation feel, easier erection, mild headache and flushing similar to tadalafil at equivalent doses. Some users report it "feels weaker" — which is consistent with the ~half-potency in vitro IC50.
  • Side effect spread (claimed): similar profile to tadalafil but compressed into shorter time window. The fundamental class side-effects (headache, back pain, dyspepsia, NAION risk, priapism risk) all plausibly carry over.

The lack of validated clinical reports means none of this should be weighted heavily.

Tolerance + cycling deep dive
  • Tolerance buildup: Unknown for nortadalafil specifically; tadalafil shows minimal receptor downregulation in years of daily dosing, and the class is generally tolerance-stable.
  • Recommended cycle: N/A — not recommended.
  • Reset protocol: N/A.
Stacking deep dive

Synergistic with

N/A — do not use, but if used, the synergy/conflict map mirrors tadalafil:

  • L-citrulline / L-arginine (NO precursors): theoretical additive
  • Methylene blue, citicoline, agmatine: mild theoretical additives via NO/cGMP nodes
  • Beta-alanine, taurine, creatine: pharmacologically neutral

Avoid stacking with (class-wide hard contraindications)

  • Nitrates of any form (nitroglycerin, isosorbide, "poppers"/amyl nitrite) — ABSOLUTE CONTRAINDICATION. Severe, potentially fatal hypotension. This is the headline FDA warning for every nortadalafil supplement recall.
  • Alpha-blockers (tamsulosin, doxazosin, terazosin) — additive hypotension
  • Riociguat / sGC stimulators — contraindicated; redundant pathway hit
  • Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit) — assumed AUC raise, but unmeasured for nortadalafil specifically
  • Strong CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) — assumed exposure drop

Neutral / safe co-administration

Unknown — no human interaction data.

Drug interactions deep dive

Assumed CYP3A4 substrate by structural analogy to tadalafil. No formal interaction studies exist. The FDA safety messaging treats nortadalafil as functionally equivalent to tadalafil for nitrate-interaction risk — which is the only interaction warning that survives the "no human data" caveat because the mechanism is so direct.

Pharmacogenomics

Unknown for nortadalafil specifically. CYP3A4/5 polymorphisms presumably matter (slow metabolizers higher AUC; ultrarapid lower) but no PGx data has been generated. NOS3 (eNOS) baseline NO production presumably modulates response magnitude as it does for tadalafil.

Sourcing deep dive
Path Vendor Cost Reliability Notes
Research chemical Kimera Chems, ApexBio, MedChemExpress $30-80 / 1 g Low "Not for human consumption" disclaimer; COA inconsistent across vendors and lots
Adulterated supplement (unintentional purchase) Various sketchy Amazon / direct-to-consumer $20-60 / bottle Zero The most common real-world exposure pathway; the user does not know he is consuming nortadalafil. FDA recalls examples: Sustain, Schwinnng, Arize, Endurea, MR.7 SUPER 700000, Vitality
Tadalafil generic (the dominant strategy instead) Indian pharmacy (AllDayChemist, ReliableRX, BuyModa, AfinilExpress) — same vendors he uses for modafinil $0.30-0.80/pill 20mg Medium-high Same gray-market sourcing reality as nortadalafil, but with FDA-validated active ingredient and 20+ years of safety data
Tadalafil generic (US legitimate) Hims, Roman, Mark Cuban Cost Plus, GoodRx + local pharmacy $10-20/mo High Telehealth Rx pathway is trivial for ED indication

The user-archetype lesson: there is no realistic sourcing scenario in which nortadalafil is preferable. Tadalafil is the cleaner product at the same price across both gray-market and legitimate paths.

Biomarkers to track (deep)
  • N/A — not recommended for use. If used despite recommendation, the class-wide tadalafil monitoring panel applies:
    • Baseline: resting BP (3-day average), HR, lipid panel, hsCRP, liver panel, baseline visual acuity
    • During use: resting + orthostatic BP, headache frequency, back/myalgia tracking, vision symptoms
    • Stop signs: any sudden vision change → ophthalmology immediately; priapism → ER
Controversies / open debates Live debate
  • Is there any legitimate use case for nortadalafil? Not for anyone with telehealth or established gray-market tadalafil access. The hypothetical case ("a researcher in a jurisdiction where tadalafil is unavailable but nortadalafil somehow is") is so narrow it doesn't apply to a US-based user.
  • Will FDA escalate nortadalafil to scheduled-drug status? Plausible — the agency has done this with sibutramine analogs and cathinone analogs after enough enforcement actions. As of 2026, nortadalafil is still treated as an "undeclared drug ingredient" rather than a separately scheduled compound.
  • Why does it keep showing up in supplements? Patent-evasion and analytical-detection-evasion. The original nortadalafil scaffold gets caught by FDA labs, so clandestine chemists iterate to N-cyclohexyl-, N-cyclopentyl-, 2-hydroxypropyl- variants. Liu 2023 and Xu 2016 are essentially the analytical-arms-race front line.
  • Half-life: 6 hours or longer? The widely cited ~6 hr figure comes from limited animal-PK and chemistry-vendor literature; one credible-but-not-registrational dataset suggests it could trend longer at lower doses. Net: not nailed down, and probably never will be without a registrational program no one will fund.
Verdict change log
  • 2026-05-10 — Initial verdict: WATCH-LIST, HIGH confidence. Rationale: the FDA-approved parent compound (tadalafil) is dominant on price, purity, PK validation, and safety data; nortadalafil's only role on this user's stack is "things to recognize and avoid" in adulterated-supplement screening.
Open questions / gaps Open
  • Will any analytical chemistry group publish a definitive human-PK study on nortadalafil? Unlikely without a regulatory mandate.
  • Selectivity panel against PDE6, PDE11 — would clarify whether nortadalafil's side effect profile differs from tadalafil's. Probably never measured rigorously.
  • FDA enforcement trajectory — escalation to scheduled status would fully close the WATCH-LIST verdict to SKIP-ALWAYS.
  • New variants in the wild — N-cyclohexyl, N-cyclopentyl, 2-hydroxypropyl already documented; the next wave (N-allyl, N-fluoroethyl, etc.) is predictable from medicinal-chemistry priors.

References

Liu et al. 2023 — Isolation and characterization of a novel tadalafil analogue adulterant, N-cyclohexyl nortadalafil, in a dietary supplement (J Pharm Biomed Anal, PMID 36841095)

pubmed.ncbi.nlm.nih.gov · 2023

analytical-chemistry detection of designer-adulterant nortadalafil variants

View Study

Xu et al. 2016 — Isolation and characterization of a tadalafil analogue, N-cyclopentyl nortadalafil in health supplement (J Pharm Biomed Anal, PMID 26580820)

pubmed.ncbi.nlm.nih.gov · 2016

earlier designer-adulterant characterization

View Study

Jin et al. 2024 — UPLC-MS/MS-Based Target Screening of 90 PDE5 Inhibitors in 5 Dietary Supplements (Molecules, PMID 39125006)

pmc.ncbi.nlm.nih.gov · 2024

detected 2-hydroxypropyl nortadalafil in nutritional wine; broad screening framework

View Study

Li, Xu, Moezzi 2021 — Identification of Erectile Dysfunction Drugs in Dietary Supplements by LC Ion Trap MS (J Diet Suppl, PMID 32351143)

pubmed.ncbi.nlm.nih.gov · 2021

LC-MS detection methodology including nortadalafil class

View Study

Tucker et al. 2018 — Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With FDA Warnings (JAMA Network Open, PMID 30646238)

pmc.ncbi.nlm.nih.gov · 2018

776 contaminated supplements 2007-2016, sexual-enhancement category dominant

View Study

FDA — Today The World Recalls Sustain and Schwinnng (Feb 2024) — undeclared tadalafil + nortadalafil

fda.gov · 2024
View Source

FDA — Today The World Recalls Arize Herbal (Feb 2024) — undeclared nortadalafil

fda.gov · 2024
View Source

FDA — Arize contains hidden drug ingredient (consumer alert)

fda.gov
View Source

FDA — ENDUREA contains hidden drug ingredients (consumer alert)

fda.gov
View Source

Tadalafil prescribing information (FDA label, Cialis)

accessdata.fda.gov

class PK / safety reference for the parent compound

View Source

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…